(Q34544889)

2 August 2017

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

2 August 2017

0 references

0 references

0 references

author name string

Diego Cadavid

series ordinal

1

1 reference

2 August 2017

Stephanie Jurgensen

series ordinal

2

1 reference

2 August 2017

Sophia Lee

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

4 January 2013

1 reference

2 August 2017

1 reference

2 August 2017

8

1 reference

2 August 2017

e53297

1 reference

2 August 2017

1

1 reference

Creative Commons Attribution 4.0 International

2 August 2017

start time

4 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Contribution of impaired mobility to patient burden in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Lymphoid chemokines in chronic neuroinflammation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537666

Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners.

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0053297

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

12 December 2020

Assessing disability progression with the Multiple Sclerosis Functional Composite

1 reference

12 December 2020

[Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0053297

Identifiers

DOI

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference